News >

Consistent Findings Validate Viability of TKI Discontinuation in CML

Caroline Seymour
Published: Thursday, Feb 14, 2019

Frank T. Slovick, MD

Frank T. Slovick, MD

First- and second-generation TKIs confer a significant survival benefit for patients with chronic-phase chronic myeloid leukemia (CP-CML)—so much so, that treatment discontinuation has become a viable option for select patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication